ReviewFrontiers in immunology2021
Role of microRNA Shuttled in Small Extracellular Vesicles Derived From Mesenchymal Stem/Stromal Cells for Osteoarticular Disease Treatment.
Review in Frontiers in immunology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 34 citations in OpenAlex.
- Luteolin in osteoarticular diseases: a review of preclinical studies and translational perspectives.Inflammopharmacology · 2026Review
- miR-1287-5p as a Biomarker for Predicting Lymph Node Metastasis in Gastric Cancer Patients.International journal of general medicine · 2026Article
- Extracellular vesicles from glycolytic mesenchymal stromal cells restrain arthritis progression via IL-10-Producing T and B cells.Theranostics · 2026Article
- Chromatin remodeling and epigenetic regulation of mesenchymal stem/stromal cells in osteoarthritis.Frontiers in genetics · 2026Review
- 3D bioprinted scaffolds for osteochondral regeneration: advancements and applications.Materials today. Bio · 2025Review
- Long-Acting Extracellular Vesicle-Based Biologics in Osteoarthritis Immunotherapy.Bioengineering (Basel, Switzerland) · 2025Review
- Synovial fluid mesenchymal stem cell-derived microRNA-127-5p can modulate transforming growth factor-β signaling after in vitro chondrogenic induction.Cytotechnology · 2025Article
- Clinical-grade extracellular vesicles derived from umbilical cord mesenchymal stromal cells: preclinical development and first-in-human intra-articular validation as therapeutics for knee osteoarthritis.Journal of nanobiotechnology · 2025Article
- Article
- MiR-29a-3p mediates phosphatase and tensin homolog and inhibits osteoarthritis progression.Functional & integrative genomics · 2024Article
- Intraarticular treatment with integrin α10β1-selected mesenchymal stem cells affects microRNA expression in experimental post-traumatic osteoarthritis in horses.Frontiers in veterinary science · 2024Article
- MiRNA regulated therapeutic potential of the stromal vascular fraction: Current clinical applications - A systematic review.Non-coding RNA research · 2023Review
- Small extracellular vesicles secreted by induced pluripotent stem cell-derived mesenchymal stem cells improve postoperative cognitive dysfunction in mice with diabetes.Neural regeneration research · 2023Article
- Role of M2 macrophages-derived extracellular vesicles in IL-1β-stimulated chondrocyte proliferation and inflammatory responses.Cell and tissue banking · 2023Article
- Progress and prospect of technical and regulatory challenges on tissue-engineered cartilage as therapeutic combination product.Bioactive materials · 2023Review
- Experimental study on repair of cartilage defects in the rabbits with GelMA-MSCs scaffold prepared by three-dimensional bioprinting.International journal of bioprinting · 2023Article
- Immunomodulatory potential of mesenchymal stromal cell-derived extracellular vesicles in chondrocyte inflammation.Frontiers in immunology · 2023Article
- Article
- Nanomedicine approaches to reduce cytokine storms in severe infections.Drug discovery today · 2022Review
- Therapeutic Strategy of Mesenchymal-Stem-Cell-Derived Extracellular Vesicles as Regenerative Medicine.International journal of molecular sciences · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 5 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Osteoarticular diseases (OD), such as rheumatoid arthritis (RA) and osteoarthritis (OA) are chronic autoimmune/inflammatory and age-related diseases that affect the joints and other organs for which the current therapies are not effective. Cell therapy using mesenchymal stem/stromal cells (MSCs) is an alternative treatment due to their immunomodulatory and tissue differentiation capacity. Several experimental studies in numerous diseases have demonstrated the MSCs' therapeutic effects. However, MSCs have shown heterogeneity, instability of stemness and differentiation capacities, limited homing ability, and various adverse responses such as abnormal differentiation and tumor formation. Recently, acellular therapy based on MSC secreted factors has raised the attention of several studies. It has been shown that molecules embedded in extracellular vesicles (EVs) derived from MSCs, particularly those from the small fraction enriched in exosomes (sEVs), effectively mimic their impact in target cells. The biological effects of sEVs critically depend on their cargo, where sEVs-embedded microRNAs (miRNAs) are particularly relevant due to their crucial role in gene expression regulation. Therefore, in this review, we will focus on the effect of sEVs derived from MSCs and their miRNA cargo on target cells associated with the pathology of RA and OA and their potential therapeutic impact.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.